Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glycopyrronium + neostigmine vs neostigmine methylsulfate + atropine for reversal of residual neuromuscular blockade
ChiCTR2500099381Phase 3Not yet recruiting
- Sponsor
- Third Xiangya Hospital, Central South University
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of glycopyrronium + neostigmine in neuromuscular block (NMB) and Heart rate changes (2 arms), sponsored by Third Xiangya Hospital, Central South University. Primary endpoints: Heart rate over time and AUC of heart rate difference vs baseline within 15 minutes. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
glycopyrronium + neostigmine
03
Conditions
neuromuscular block (NMB)Heart rate changes
Beyond the preview
Go deeper on ChiCTR2500099381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099381.